drugset
drugset / Trial / NCT04497038

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

NCT04497038 ↗

Phase 1/2 Terminated 3 enrolled University of Michigan Rogel Cancer Center Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to determine the safety and efficacy of cabozantinib in the management of unresectable or metastatic hepatocellular carcinoma (HCC) with underlying Child-Pugh class B cirrhosis.

Timeline

Start
2021-08-06
Primary completion
2023-05-02
Completion
2023-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule 40 mg Oral

Indications

adult hepatocellular carcinoma